• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

质量范围法在分析相似性评价中的局限性:均值偏移和相对变异性的影响。

Limitations of the quality range approach in analytical similarity assessment: Effect of mean shift and relative variability.

机构信息

Departamento de Ingeniería Química y Tecnología Farmacéutica, Facultad de Farmacia, Universidad de La Laguna, 38200, Tenerife, Spain.

Departamento de Ingeniería Química y Tecnología Farmacéutica, Facultad de Farmacia, Universidad de La Laguna, 38200, Tenerife, Spain.

出版信息

J Pharm Biomed Anal. 2021 May 10;198:114017. doi: 10.1016/j.jpba.2021.114017. Epub 2021 Mar 10.

DOI:10.1016/j.jpba.2021.114017
PMID:33730613
Abstract

Recently in 2019, the United States Food and Drug Administration (FDA) circulated a new draft guidance for comparative analytical assessment. They suggest the use of quality range (QR) methods. In this article, selection of the k value, and the effect of mean shifts and relative variability are evaluated. These are expressed as a ratio between the two standard deviations of the tested product and the reference product, σ/σ. In a second step, the two modified versions of the QR method proposed by Son et al. (2020) are also analysed under several scenarios, through simulation studies using real data from a biotechnology company and our own data for bevacizumab. Results indicate that k has a great impact on the probability of passing similarity tests. Pass rates higher than 90 % can be achieved for small relative variabilities (σ/σ ≤ 0.6) and large mean shifts (≈4%) by using k = 3. The situation is totally different for k = 2: the pass rate is higher than 90 % for scenarios with small (<0.5 %) or no differences between the means of the two products, but this percentage decreases by up to 50 % for σ/σ = 1. Effectiveness in detecting the various scenarios was quantified by calculating the probability curves of passing the similarity test, as a function of the two variables for each k value. Alternative methods present the same limitations but with different magnitude in comparison with QR, this being most pronounced in the plausibility-interval QR method.

摘要

最近,2019 年,美国食品和药物管理局(FDA)发布了一份关于比较分析评估的新草案指南。他们建议使用质量范围(QR)方法。在本文中,评估了 k 值的选择以及均值偏移和相对变异性的影响。这些是通过将测试产品和参比产品的两个标准差之比,即 σ/σ 来表示的。在第二步中,还通过使用生物技术公司的真实数据和我们自己的贝伐珠单抗数据进行模拟研究,分析了 Son 等人(2020 年)提出的 QR 方法的两种改进版本。结果表明,k 值对通过相似性测试的概率有很大影响。通过使用 k = 3,可以在相对变异性较小(σ/σ ≤ 0.6)和均值偏移较大(≈4%)的情况下实现通过率高于 90%。对于 k = 2 来说,情况则完全不同:在两个产品之间的均值差异较小(<0.5%)或没有差异的情况下,通过率高于 90%,但对于 σ/σ = 1,这一百分比会下降多达 50%。通过计算相似性测试通过的概率曲线,作为每个 k 值的两个变量的函数,量化了检测各种情况的有效性。与 QR 相比,替代方法具有相同的局限性,但程度不同,在似然区间 QR 方法中最为明显。

相似文献

1
Limitations of the quality range approach in analytical similarity assessment: Effect of mean shift and relative variability.质量范围法在分析相似性评价中的局限性:均值偏移和相对变异性的影响。
J Pharm Biomed Anal. 2021 May 10;198:114017. doi: 10.1016/j.jpba.2021.114017. Epub 2021 Mar 10.
2
Some thoughts on the QR method for analytical similarity evaluation.关于分析相似度评价 QR 法的一些思考。
J Biopharm Stat. 2020 May 3;30(3):521-536. doi: 10.1080/10543406.2020.1726372. Epub 2020 Feb 23.
3
On Statistical Approaches for Demonstrating Analytical Similarity in the Presence of Correlation.关于在存在相关性的情况下证明分析相似性的统计方法。
PDA J Pharm Sci Technol. 2016;70(6):547-559. doi: 10.5731/pdajpst.2016.006551. Epub 2016 Jun 20.
4
On the establishment of equivalence acceptance criterion in analytical similarity assessment.论分析相似性评估中等效性接受标准的建立。
J Biopharm Stat. 2017;27(2):206-212. doi: 10.1080/10543406.2016.1265539. Epub 2017 Jan 4.
5
Statistical considerations regarding correlated lots in analytical biosimilar equivalence test.分析性生物类似药等效性试验中相关批次的统计学考量
J Biopharm Stat. 2017;27(2):213-219. doi: 10.1080/10543406.2016.1265541. Epub 2016 Dec 1.
6
A Novel Bootstrapping Test for Analytical Biosimilarity.一种分析性生物类似药的新型自举检验方法
AAPS J. 2022 Oct 21;24(6):112. doi: 10.1208/s12248-022-00749-3.
7
Analytical Similarity Assessment in Biosimilar Studies.生物类似药研究中的分析相似性评估
AAPS J. 2016 May;18(3):670-7. doi: 10.1208/s12248-016-9882-5. Epub 2016 Feb 12.
8
Development of statistical methods for analytical similarity assessment.用于分析相似性评估的统计方法的开发。
J Biopharm Stat. 2017;27(2):197-205. doi: 10.1080/10543406.2016.1272606. Epub 2016 Dec 15.
9
On sample size requirement for analytical similarity assessment.关于分析相似性评估的样本量要求。
J Biopharm Stat. 2018;28(6):1143-1159. doi: 10.1080/10543406.2018.1437171. Epub 2018 Mar 7.
10
Analytical and functional similarity of Amgen biosimilar ABP 215 to bevacizumab.安进生物类似药 ABP 215 与贝伐珠单抗的分析和功能相似性。
MAbs. 2018 May/Jun;10(4):678-691. doi: 10.1080/19420862.2018.1452580. Epub 2018 Apr 20.

引用本文的文献

1
Assessing Protein Content and Dimer Formation in the Bevacizumab Reference Product and Biosimilar Versions Marketed in Spain.评估在西班牙销售的贝伐单抗参比制剂和生物类似药版本中的蛋白质含量及二聚体形成情况。
Pharmaceutics. 2024 Nov 26;16(12):1520. doi: 10.3390/pharmaceutics16121520.
2
Determining Critical Thresholds of Environmental Flow Restoration Based on Planktonic Index of Biotic Integrity (P-IBI): A Case Study in the Typical Tributaries of Poyang Lake.基于浮游生物完整性指数(P-IBI)确定水生态修复的关键阈值:以鄱阳湖典型支流为例。
Int J Environ Res Public Health. 2022 Dec 22;20(1):169. doi: 10.3390/ijerph20010169.
3
New Quality-Range-Setting Method Based on Between- and Within-Batch Variability for Biosimilarity Assessment.
基于批次间和批次内变异性的生物相似性评估新质量范围设定方法
Pharmaceuticals (Basel). 2021 Jun 1;14(6):527. doi: 10.3390/ph14060527.